News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
10SET（Tenset） 24-hour volatility at 348.0%: Active trading with low liquidity triggers price rebound
Bitget Pulse·2026/03/17 15:06
Bitcoin Layer 2 Stacks says its latest upgrade boosts DeFi capacity by up to 30x
The Block·2026/03/17 14:57
Bitcoin’s Post-Quantum Upgrade Timeline and the Risk of Consensus Failure
DeFi Planet·2026/03/17 14:51
JPY: Two way economic risk for Japanese Yen – Rabobank
101 finance·2026/03/17 14:42
A $50 Trillion Bet on Tokenization: How Abundance Assets Could Shape DeFi’s Next Growth Phase
DeFi Planet·2026/03/17 13:51
'Bitcoin Standard' author explores reality where decentralized gold stopped WWI
Cointelegraph·2026/03/17 13:33
Japan's Power Semiconductors: From Glory to Decline
华尔街见闻·2026/03/17 13:18
Expert Says It’s 9x Easier Right Now to Push XRP to $2.25 Than to $0.75. Here’s Why
TimesTabloid·2026/03/17 13:06
Flash
12:38
Cannae Holdings, Inc. has successfully completed the full acquisition of Exeter Rugby Group, significantly advancing the company's strategic shift to focus its investments on sports and entertainment assets.By acquiring full ownership of the rugby club, Cannae Holdings further consolidates its presence in the sector, aiming to identify and integrate high-value entertainment assets. This strategic acquisition not only expands the company's asset portfolio but also positions it more advantageously in the rapidly evolving sports entertainment market.
12:38
Moleculin Biotech, Inc. (Moleculin) recently announced the interim analysis results of its phase 2/3 "Miracle" clinical trial, showing positive data.The results show that the core candidate drug Annamycin demonstrated significantly superior efficacy in inducing complete remission compared to the control group, with the complete remission rate reaching three times that of the control group. This positive data provides strong momentum for the further development of Annamycin in the treatment of acute myeloid leukemia. The success of the interim analysis indicates that the drug has made breakthrough progress in key efficacy indicators, and it is expected to offer new treatment options for patients. The company will continue to advance clinical trials to obtain more confirmatory data.
12:37
U.S. Stock Index Futures Turn Lower On June 30, Dow Jones futures fell by 0.11%, S&P 500 futures declined by 0.07%, and Nasdaq 100 futures decreased by 0.05%.
News